Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Survival in patients with pancreatic cancer remains low

Treatment factors are related to survival time in pancreatic cancer, although there is racial disparity in therapies, reports September's American Journal of Surgery.

News image

fiogf49gjkf04

Dr Mohamad Eloubeidi and investigators performed a population-based study of patients from the deep South of the United States.

The investigative team evaluated the survival rate of patients with pancreatic cancer.

The team analyzed prognostic factors influencing pancreatic cancer survival using the Alabama Statewide Cancer Registry.

The investigators determined whether race/ethnicity is an independent determinant of outcomes in patients with pancreatic cancer.

The team included eligible participants diagnosed with pancreatic cancer from 1996 to 2000 and reported to the Alabama Statewide Cancer Registry.

Survival time was calculated from time of diagnosis to death for pancreatic cancer deaths.

The team also calculated survival time from the time of diagnosis to date of last contact or death from other causes for censored participants.

Risk factors associated with survival were assessed with the Kaplan-Meier survival method and the log-rank test.

The median survival time for all patients was less than 5 months
American Journal of Surgery

Demographic, tumor, and treatment variables were assessed using the Cox proportional hazards model.

The investigators evaluated 2230 patients, whose median age at diagnosis was 71 years with a male to female ratio of approximately 1 to 1.

Of these patients, 73% were white, and 27% were black.

The distribution by stage was 13% localized disease, 30% regional, 35% distant, and 23% unstaged.

The median survival time for all patients was less than 5 months.

The investigators noted that patients who underwent surgical treatment were less likely to die of pancreatic cancer.

Similarly, patients who underwent either chemotherapy or radiation therapy had improved survival rates.

Across all stages, the team observed that black patients were significantly less likely to receive chemotherapy compared with white patients.

These patients were less likely to receive surgical intervention.

When examining patients who were offered their therapy of choice but refused, the team found that a greater proportion of black patients refused therapies.

For chemotherapy, 4% of black patients refused therapy versus 2% of white patients.

The team noted that for radiation, and 9% of black patients refused therapy versus 3% of white patients.

The Cox proportional hazard model showed no effect of race on overall survival time while controlling for stage at presentation.

In addition, the investigators observed no effect of race on survival controlling for type of therapy received, age at diagnosis, and site of primary tumor.

Dr Eloubeidi's team concluded, “Survival in patients with pancreatic cancer remains dismal.”

“Tumor characteristics and treatment factors are related directly to survival time in patients with pancreatic cancer.”

“Black patients were less likely to receive therapy but also were more likely to refuse the indicated therapy.”

“Factors leading to racial disparity in the treatment of pancreatic cancer warrant further investigation.”

Am J Surg 2006: 192(3): 322-9
29 August 2006

Go to top of page Email this page Email this page to a colleague

 26 February 2018 
Metabolic effects of new therapies of NASH
 26 February 2018 
Hepatocellular carcinoma risk in Hep B
 26 February 2018 
Novel targets for hepatocellular carcinoma
 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
MRI and NAFLD
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us